Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
Globe Newswire•29/10/2026•09:00 ET
0
Key Highlights
- ➤ART27.13 reduced mechanical allodynia and thermal hyperalgesia in male and female animals
- ➤Phase 2 CAReS trial includes multiple pain endpoints for cancer-related symptoms
- ➤Highest-dose CAReS patients gained 6% body weight over 12 weeks
- ➤Placebo patients lost approximately 5% additional body weight over 12 weeks
- ➤Paclitaxel-induced peripheral neuropathy affects approximately 60% to 80% of patients
Expert Statements
Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo
“Cancer patients frequently experience multiple debilitating symptoms, including appetite loss, weight loss and neuropathic pain, yet treatment options remain limited.”
Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo
“Our nonclinical findings demonstrate ART27.13's potential to reduce chemotherapy-induced neuropathic pain, complementing the encouraging weight gain and activity improvements observed from our Phase 2 CAReS trial’s interim analysis.”
Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo
“Importantly, the trial already includes pain endpoints, providing an opportunity once CAReS is completed to evaluate whether ART27.13 could address multiple cancer-related symptoms through a single, once-daily oral therapy.”
Nonclinical studies demonstrated reductions in two key measures of neuropathic pain
Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple cancer-related symptoms
Get started
Create a free account to read the full story.